Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice.
Lipsky
P E
PE
Abramson
S B
SB
Breedveld
F C
FC
Brook
P
P
Burmester
R
R
Buttgereit
F
F
Cannon
G W
GW
Catella-Lawson
F
F
Crofford
L J
LJ
Doherty
M
M
Dougados
M
M
DuBois
R N
RN
Froelich
J
J
Garcia Rodriguez
L A
LA
Gibofsky
A
A
Hernandez-Diaz
S
S
Hochberg
M C
MC
Krause
A
A
Liang
M H
MH
Machold
K
K
Peloso
P M
PM
Raisz
L G
LG
Schayes
B
B
Scheiman
J M
JM
Simon
L S
LS
Smolen
J
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D051546:Cyclooxygenase 2; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D008565:Membrane Proteins; D010146:Pain / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases